Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms

Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neopla...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Turk J Haematol
Main Authors: Eliaçık, Eylem, Işık, Ayşe, Aksu, Salih, Üner, Ayşegül, Büyükaşık, Yahya, Sayınalp, Nilgün, Göker, Hakan, Özcebe, Osman İ., Haznedaroğlu, İbrahim C.
Formato: Artigo
Idioma:Inglês
Publicado em: Galenos Publishing 2015
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451485/
https://ncbi.nlm.nih.gov/pubmed/26316485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.2013.0265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados